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Heterogeneity in learning processes and the evolution of dynamic managerial capabilities 
as a response of emergence of biosimilar market: Evidence from the Indian 
pharmaceutical industry 
 
Abstract 
This paper examines heterogeneity in the response of Indian firms to the emergence of a new 
segment in the pharmaceutical generics market - biosimilars. The necessary diversity of the 
knowledge base and regulatory requirements underlying biosmilar products have created 
significant technological capability and market access challenges for Indian firms. This is but 
the latest development which adds to an existing catalogue of challenges including the decline 
of the traditional generics markets, regulatory hurdles in advanced country markets and failures 
in managing new drug development. Using case studies of three Indian firms we show that 
dynamic managerial capability is a key driver of heterogeneity in learning processes involved 
in acquisition of technological capabilities for biosimilars and market access strategies. It 
further highlights the important role of pre-existing capabilities in enabling and constraining 
the development of new biosimilar capabilities.   
 
Key words: India, dynamic capabilities, pharmaceutical industry, heterogeneity 
  
  
2 
1.0 Introduction 
In the last two decades, the ways firms respond to changes in the external environment has 
emerged as a major concern of the dynamic capability and industry evolution literature (Helfat 
and Winter, 2011; Teece et al., 1997). In response, Adner and Helfat (2003) highlight the impact 
of managers on strategic change by presenting the dynamic managerial capabilities concept – 
the capacities with which managers create, extend and modify the ways in which firms respond 
to change. To a large extent, the dynamic capability and dynamic managerial capability 
literature has focused on firms in advanced countries. In developing countries, however, the 
challenge for firms is more demanding as local technological, political and economic realities 
complicate the transformation of capabilities (Amann and Cantwell, 2013). This paper 
addresses a gap in the current literature by investigating response of Indian pharmaceutical 
firms to the emergence of a market for biosimilars. 
 
Biosimilars are generic versions of biological drugs. The market for biosimilars is growing and 
represents a significant opportunity for the Indian biotech and pharmaceutical industries. The 
complexity of biological drugs and extensive regulatory requirements however, has meant both 
challenges and opportunities for developing country firms (Huzair and Kale, 2011). In this 
context, the Indian pharmaceutical industry provides us with informative case studies with 
which we may explore the development of dynamic capabilities by resource-constrained firms.  
 
Post 2000, the Indian pharmaceutical industry emerged as a global supplier of cheap generic 
drugs. A decade on, increasingly competitive generic markets in advanced countries are 
witnessing a significant drop in value (Kamath, 2011). For leading Indian firms this market 
challenge is further compounded by regulatory hurdles in advanced country markets and 
failures in managing new drug development, raising important questions for long-term growth 
and survival. This gives rise to the key research question; how are firms reconfiguring their 
strategies for the development of capabilities in response to the emergence of biosimilar market 
opportunities?  
 
Using case studies of three Indian firms we show the heterogeneity in firms’ reconfiguration 
strategies and further explore the origin of heterogeneity when different firms operate in the 
same environment with the same resource base. Our paper makes three critical contributions to 
the dynamic capabilities and industry evolution literatures. First, it demonstrates how a change 
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in market re-orientates technological capabilities even in the absence of a radical technological 
discontinuity. Second, the paper shows dynamic and managerial capabilities applied to three 
areas; diversification of the knowledge base, technological (production) capability and 
regulatory affairs. The distinction between dynamic capabilities and managerial capabilities can 
be difficult to do in practice, but is attempted by this work as we draw that distinction and 
demonstrate how they interact. Third, this paper demonstrates how pre-existing technological 
capability which served small molecule generic markets, are not necessarily abandoned. In this 
case, where significant risk and uncertainty exists, achieving a balance between generics 
production and investment in biosimilars is key to survival in the short term.  
 
This paper is structured as follows: Section 2 reviews key literature on heterogeneity and the 
dynamic capabilities approach. Section 3 explains the salient features of the Indian 
pharmaceutical industry and challenges to existing business models. Section 4 discusses size 
and growth of the biosimilar market, and tracks the challenges of the biosimilar capability 
development for emerging country firms. Section 5 details our data collection methods and the 
three Indian pharmaceutical firm case studies that are used to illustrate the evolution of firm 
strategy and biosimilar R&D capability. In section 6 we present our results on the different 
strategies and the reconfiguration of capabilities of Indian pharmaceutical firms in response to 
market opportunities. Section 7 concludes.   
 
2.0 Firm strategies and dynamic capabilities 
Firm capabilities were explored as early as 1959 in the works of Penrose who suggested that 
the growth of firms is conditioned by their resources and the desire to fully exploit them.  Helfat 
and Winter (2011: 1244) define capability as “the capacity to perform a particular activity in a 
reliable and at least minimally satisfactory manner”. Highlighting connection between 
objective, purpose and an intended outcome, Dosi et al. (2000:2), suggest “capabilities fill the 
gap between intention and outcome, and they fill it in such a way that the outcome bears a 
resemblance to what was intended”.  
 
Firm capabilities evolve over time as firms encounter endogenous market changes and 
exogenous shocks (Athreye et al., 2009). In markets where the competitive landscape is 
continuously shifting, dynamic capabilities become the source of competitive advantage (Teece 
et al., 1997). Here ‘dynamic capabilities’ refer to the “firm’s ability to integrate, build and 
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reconfigure internal and external competencies to address rapidly changing environments” 
(Teece et al., 1997:516). These capabilities are rooted in high performance routines operating 
inside in the firm, embedded in firm’s processes, and are conditioned by its history.  
 
Eisenhardt and Martin (2000) add that dynamic capabilities are a set of identifiable processes 
including product development, strategic decision-making and alliancing, which are path 
dependent. Following from this, Adner and Helfat (2003) introduced the concept of dynamic 
managerial capabilities to help explain the relationship between managerial decisions and 
actions, strategic change, and corporate performance under conditions of change. This strand 
of research extends the dynamic capabilities perspective by understanding the role of managers 
both as individuals and within teams (Helfat and Martin, 2015). Helfat and Martin (2015) 
explicitly link heterogeneity in firm’s performance and strategies with firm specific dynamic 
managerial capabilities. They emphasise the influence of the ‘asset orchestrating’ role-played 
by firm specific managerial capabilities in shaping strategic change. However, Helfat and 
Martin (2015) suggest that these strands of the literature have failed to explore how interactions 
between dynamic managerial capabilities and resources, influence strategic change.  
 
Relatively few studies on emerging countries have attempted to explain variability in latecomer 
firms’ strategies and dynamic capabilities (Amann and Cantwell, 2013) or the building of firm 
level innovative capabilities (Mathews, 2006; Kim and Nelson, 2000).  Bell and Figueiredo 
(2013) argue that the study of dynamic capability development in latecomer firms has been 
limited and under researched except for Amsden and Tschang (2003), Dutrenit (2000) and 
Athreye et al. (2009). This paper builds-on and adds to the research focused on the evolution of 
dynamic managerial capabilities in emerging country firms by focusing on Indian firms’ 
responses to the emergence of a biosimilar sector.  
 
This paper goes beyond establishing a descriptive portrait of firm level processes involved in 
the development of technological capabilities to engage with the question of how different 
strategies and therefore capabilities arise in emerging pharma firms, despite common 
constraints.  
 
3.0 The Indian pharma-biotech industry  
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The Indian pharmaceutical industry ranks 12th in the world in terms of value and by volume is 
the second largest in the world.  In last few decades, Indian pharma industry emerged as 
‘pharmacy of the world’ by dominating small molecule generic markets using their superior 
process R&D skills, cheap production processes and strong marketing capabilities (Kale and 
Wield, 2008). In recent years, however, the Indian pharmaceutical industry has faced key 
challenges such as a significant decline in value of small molecule generics markets, increased 
regulatory scrutiny by the FDA and the high rates of failure associated with bringing innovative 
drugs to market. In this context, biosimilars presented an opportunity for growth and 
diversification. The significance of biosimilars is explained by the R&D head of a leading 
Indian firm; 
“Biosimilars are extremely important in two dimensions: from a very local healthcare 
market perspective this class of drugs are very influential in management of human 
health disease. This is critical from a simple perspective of making medicines available 
to people. From a more global perspective how does Indian pharma compete and where 
is that we continue to be relevant in the global industry to me this clearly represents one 
of the areas that we must move towards.”  
For resource constrained Indian firms this significant shift in global generics markets will 
demand a new set of R&D, regulatory and marketing capabilities.  
 
4.0 The emergence of a new market: Biosimilars  
The growth in the biosimilar market is driven by several factors including original biologics 
coming off patent, pressure on governments to reduce healthcare costs and development of 
regulatory guidance in key markets. Biologicals account for an increasing portion of newly 
approved therapies for chronic inflammatory diseases, arthritis and cancer and biosimilars are 
poised to acquire a significant share of the generics pharmaceutical market (Wechsler, 2011). 
Switching to biosimilars is not an easy, minimum risk strategy, but a decision that requires 
considerable financial and organisational investment in developing regulatory, technical and 
scientific capabilities. The technical competencies that are required to manufacture biologics 
and biosimilars include abilities to generate pharmacovigilance and bioequivalence data.   
 
4.1. The challenge of a knowledge base  
Over the years Indian pharma firms have developed a knowledge base firmly embedded in 
organic and synthetic chemistry. In the case of biosimilars, these firms need expertise to reverse-
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engineer biologics and develop stable, therapeutically active cell lines. Attempts to create a 
generic version of a reference biologic is likely to produce a product with some degree of 
variation. Understanding the possibility and consequences of even small variations require 
knowledge in new fields of biology. Firms producing biosimilars also need to develop 
manufacturing processes to meet specifications and to invest in new infrastructures for 
controlling living cells, purification, and producing biologic products consistently at 
commercial scale (Lee et al., 2011). The main constraint for Indian firms is the lack of expertise 
in areas of biology and biotechnology pertinent to biosimilars. A senior scientist in Serum 
Institute of India explains; 
“In biosimilar development it is quite hard to spot small differences in production 
processes. These can lead to significant changes to drug safety and efficacy. But in India 
there are very few people who have this knowledge.”  
 
4.2 The challenge of regulatory requirements   
Indian firms are also facing the challenge of developing biosimilar focused regulatory 
capabilities. Regulatory frameworks particularly in advanced country markets, demand 
extensive data on clinical trials and immunogenicity. The evolving nature of regulation, is 
creating financial and technological capability challenges for Indian firms. The head of R&D 
in an Indian firm comments, 
“I mean everybody sees the biosimilar opportunity but the question is how many can do 
it. The key question is how many firms in India can create their own teams that can 
develop biosimilars globally? I will separate the ability question from the funding 
question.  In many ways, the funding question is easier to answer than the ability 
question.”  
 
5.0 Strategy and dynamic capabilities: Case studies of three firms  
The Indian biosimilar market is worth around US$380 million and has been growing at a CAGR 
30% since 2008 (Huzair and Kale, 2015). There are approximately 20 Indian firms with 
technological capabilities in the manufacture of recombinant products and these may 
foreseeably produce biosimilars (GABI, 2015).  To explore Indian firms’ strategies, we will 
present case studies of three Indian pharmaceutical firms (Table 1).  
     
Table 1 Firms studied in the present research (Annual Reports, 2013) 
  
7 
Firms Nature of 
firm 
Turnover 
2012-13 
US $ mn  
R&D 
intensity 
(2013) 
Biosimilar  Supply of 
Biosmilar in 
overseas 
market 
Biocon   Biotech 364.16 
 
10% 
 (US $ 
36.4 mn) 
Human insulin, Insulin 
Glargine, Erythropoietin, 
Filgrastim, Streptokinase, 
Itolizumab, Transtuzumab 
27 countries 
Cipla 
 
Pharma 1545.00  4.9%  
(US $ 79.5 
mn) 
Etanercept, Darbepoetin 
alfa’ 
India 
DRL  Pharma 1560.00 6.6%  
(US $ 
143.6 mn) 
Filigrastim, Rituximab, 
pegfilgrastim, darbepoetin 
alpha 
12 countries  
 
Primary data for the case studies was collected through interviews with R&D presidents, senior 
scientists and heads of biotech R&D in the three firms. We also conducted interviews with a 
key member of the Indian pharmaceuticals industry association and with a senior sector 
specialist journalist. Data was triangulated by using information in annual reports, analysts’ 
presentations and articles in the business press. Interviews focused on firm strategy, challenges 
and organisational learning activities involved in the acquisition of new knowledge required for 
biosimilar development, the relevance of existing pharmaceutical R&D and manufacturing in 
the development of biosimilar capabilities.   
 
Our reasons for focussing on these firms are threefold. One, the firms selected for study are in 
different stages of developing biosimilar product portfolios and thus provide ideal cases to study 
the reconfiguration of firm level capabilities. Biocon and DRL are early entrants while Cipla is 
a late entrant. Second, these cases provide a mix of different types of Indian firms with 
biosimilar capabilities; pharma firms (Cipla), biotechnology dedicated firms (Biocon) and 
pharma-biotech firms (DRL). This allows us to examine the significance of path dependency, 
differences in strategies and the role of established routines in the reconfiguration of 
capabilities. Third, all these firms are family owned businesses with strong leaders, thus 
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providing an opportunity to track influence of managerial capabilities on strategic change and 
heterogeneity in learning processes. The firms under study are not representative of the whole 
pharmaceutical industry. The study is not intended to extrapolate beyond that fraction of the 
industry which is dedicated to the manufacture of biologicals. These firms do however 
exemplify how firms in emerging countries develop more sophisticated capabilities in 
biological production from a basis generics production or biotechnology. We argue that this 
study is important not only because it demonstrates what will be happening in other emerging 
countries but because biosimilar producers can potentially and significantly impact the costs of 
health care globally.  
 
5.1 Biocon: The dedicated biotech firm  
Hot on the heels of US biotech firms like Genentech, which for the first-time cloned insulin in 
1978, Biocon was established in 1978 by Kiran Muzumdar Shaw. Her aim was to develop a 
fully integrated biotechnology company focused on biopharmaceuticals, custom and clinical 
research. In 1979 it became the first Indian company to manufacture and export enzymes to the 
US and Europe. Throughout 1990s, however, the company maintained its focus on 
biopharmaceuticals and set up an in-house biotech research programme. The main milestones 
in the company’s biosimilar capability development are summarised in fig 1. 
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Fig 1 Biocon Laboratories  
 Decides biopharmaceuticals as future area of growth and starts focusing on manufacturing of statins; 
cholesterol reducing drugs  
1990 
2000 
2001 
2003 
2013 
2006 
2008 
2009 
2010 
 Establishes Cyngene for clinical trials and an alternative source of revenue  
 
Becomes the first Indian company to be approved by FDA to manufacture and sell Lovastatin in the US. 
 
Becomes the first company to produce human insulin on a Ptichia expression system, enters emerging country 
markets 
Sets up biotech R&D and manufacturing unit in Bangalore, hires Dr. Barve from USA to lead biotech R&D 
. 
Acquires 78% stake in German pharmaceutical company, AxiCorp GmbH for €30 Million to access German 
market, dissolves stake in 2011 but keeps right to market   
Forms partnership with Mylan to co-develop and market 3 biosimilars, starts work on manufacturing 
facility in Malaysia  
Forms partnership with Pfizer to globally commercialise several of Biocon's insulin products, Pfizer 
dissolves this partnership in 2012 
Biocon and Mylan receives Indian regulatory Approval for Trastuzumab for Treating Breast 
Cancer and launches product in Indian market  
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2006 marks a crucial point in the company’s history, with the development of a more 
sophisticated biosimilar strategy to target cancer. 8 years prior, Genentech had launched a first-
in-class monoclonal antibody therapy for breast cancer, Herceptin (Trastuzumab), which 
proved to be extremely profitable. With patent expiration in 2014 in Europe and in 2019 in the 
US, Biocon identified the potential for a biosimilar to compete in this area and developed 
capacity accordingly. In 2006 Biocon established India’s largest multi-product Biologicals 
R&D facility in Bangalore, focusing on diabetes and oncology.  The company filled knowledge 
gaps through collaborative R&D partnerships and by building a strong, focused research team. 
In 2006 Biocon entered a joint venture with the Cuban Institute of Monoclonal Antibodies to 
develop cancer therapies, followed by a joint venture with Abraxix Bioscience to develop a 
biosimilar version of Filgrastim (commonly used in oncology) in 2007. In the same year, 
Biocon hired Dr Barve from a US biotech firm to lead its clinical research division and later to 
head biotech R&D.  Under his leadership, Biocon adopted an aggressive strategy of targeting 
overseas markets through various collaborations and joint ventures (Fig 1). In 2009 Biocon 
formed a strategic joint venture with Mylan, an MNC generics firm, to co-develop four 
biosimilars and enter the global biosimilar market. In 2013, the Biocon – Mylan partnership 
achieved its first success with regulatory approval for its own version of Trastuzumab.    
 
Biocon’s successful growth into a fully integrated biotech company with a strong biosimilar 
portfolio and an extensive presence in international markets was founded on a targeted 
programme of organic growth and investments in biotech R&D. It showed a good foresight in 
grasping the significance emerging biosimilar markets long before other firms. In expanding its 
R&D capability the firm paid attention to human resource recruitment to fill knowledge gaps 
and initiate collaborations to enter international markets.  
 
5.2 Cipla: A traditional pharmaceutical firm  
Cipla (Chemical, Industrial and Pharmaceutical Laboratories Ltd) was established in 1935 
by Dr A K Hamied and emerged as a leader in the 1970s with its ability to reverse engineer 
patented molecules, successfully launching low priced generics in India. Over the last five 
decades Cipla developed extensive capabilities in process R&D and has emerged as a global 
supplier of cheap generic drugs. Cipla transformed the global HIV-AIDS treatment landscape 
by launching antiretroviral drugs in emerging countries at comparatively low price. It gave 
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boost to Cipla’s international generics strategy and by 2012 emerged as  one of the most 
successful Indian firms with an average annual growth rate of over 20%. 
 
In post TRIPs era, the transformation of the Indian domestic market and increased competition 
from global generic manufacturers forced Cipla to embrace biosimilars as a key area of future 
growth.  But to achieve success in the biosimilar market, Cipla faced major hurdles in the form 
of R&D and manufacturing capabilities and lacked the professional management required to 
manage international expansion in the emerging biosimilar market. To overcome these 
knowledge gaps Cipla embarked on a two-pronged strategy (fig 2). First it acquired biotech 
firms and entered inward co-licensing deals. Second, it created management teams experienced 
in international expansion by hiring senior management professionals from competitor MNC 
firms.  
 
To accelerate biosimilar development in 2004 Cipla created Avesta Biologicals Ltd, a new 
biotech company in partnership with Avesthagen, an Indian biotech company. Avesthagen was 
responsible for biosimilar R&D while Cipla’s role was to scale-up and manage sales and 
distribution in domestic and international markets. In 2007, Avesta Biological acquired 
Siegfried Biologicals, a biotech company based in Germany, to access biological R&D 
expertise. Siegfried was a contract-manufacturing company with experience in the development 
of biologicals including cell line generation, upstream process development and scale-up of 
manufacturing processes that comply with Good Manufacturing Practices (GMP). However in 
2009 Cipla decided to dissolve Avesta Biologicals and Therapeutics due to lack of progress in 
biosmilar development.   
 
To overcome this failure, in 2010 Cipla acquired a 25% stake in MabPharm, an India based 
biotech firm. In 2011, Cipla helped MabPharma set up a state of the art biotechnology 
manufacturing facility in India and in 2014, Cipla gained full ownership of the manufacturing 
plant by acquiring the remaining 75% share. In parallel to the MabPharm acquisition, Cipla 
invested $65 million to acquire a 40% stake in Bio Mabs, a Shanghai based biotech aimed at 
developing ten monoclonal antibody drugs and fusion proteins for rheumatoid arthritis, cancers 
and asthma for marketing in India and China.  
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To complement these acquisitions, Cipla decided to build a biosimilar product portfolio through 
in-licencing. In 2013, Cipla launched its first biosimilar product, Etanercept, through in-
licensing from China-based Shanghai CP Guojian Pharmaceutical Co. In 2014, Cipla in-
licensed a second biosimilar, ‘Darbepoetin alfa’, by entering a co-marketing deal with Hetero 
Drugs, an Indian biotech company.  
 
In 2012, a new management team initiated a strategy to convert the various partnerships into 
subsidiaries and joint ventures to bolster complimentary capabilities. In 2012, Cipla acquired 
its distribution partner in South Africa and increased its stake in a Uganda-based joint venture. 
In 2013, Cipla acquired a 100% stake in its Croatian distributor, a 51% stake in its UAE 
distributor and a 60% stake in a pharmaceutical company based in Sri Lanka. Cipla aims to start 
selling both its biosimilar products in international markets using these newly acquired 
marketing and distribution entities.
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Fig 2 Cipla Laboratories Ltd 
 
 
 Decides to focus on biosimilars as future area of growth; targets Roche’s largest selling 3 biological products  
 
2000 
2004 
2007 
2009 
2010 
2013 
2014 
Establishes Avesta Biologicals Ltd and Therapeutics in partnership with Avesthagen (an Indian biotech 
company) to co-develop biosimilars  
Avesta Biologicals acquires Siegfried Biologicals, a German biotech company with extensive experience in 
development of biological products 
Dissolves Avesta Biological due to lack of success and acquires 25% stake in Mabpharm, an Indian biotech 
company involved in development of biosimilar products  
Acquires 40% BioMabs, a Chinese bioetch company. Cipla helps Mabpharm to set up biotech manufacturing 
facility 
Acquires 75% of MabPharma and biotech manufacturing facility, in-licenses ‘etarncept’ from China-based 
Shanghai CPGuojian Pharmaceutical, launches in India at 30% lower price than innovator’s product 
In-licenses Darbepoetin alfa, used in the treatment of chronic kidney disease, from Hetero Drugs to market 
in the Indian domestic market  
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In the biosimilar market Cipla is creating a product portfolio through in-licensing and investing 
in expanding its international presence by converting its existing partnerships into company 
owned subsidiaries. This indicates that the company is using its strong complimentary 
capabilities in the form of sales and distribution infrastructure while depending on partnerships 
and acquisitions for creating a biosimilar portfolio.  
 
5.3 Dr Reddy’s Laboratories (DRL): A biopharmaceutical firm 
DRL was founded in 1984 by Dr Anji Reddy with the aim of creating an innovative Indian 
pharmaceutical company. DRL set up biotechnology R&D in 1999 as a separate business unit 
and within two years launched its first biosimilar product, Filgrastim. In 2003, this effort 
received a boost with the hiring of Dr Cartikeya Reddy from Genentech Corporation as head of 
the Biological division. Reddy helped DRL to accelerate the development of its biosimilar 
business and in a period of 10 years succeeded in launching three more biosimilars; Darbepoetin 
Alfa, Pegfilgrastim and more significantly Rituximab. Rituximab, launched in 2007, DRL was 
a milestone for the company in terms of its biosimilar program as it was their first monoclonal 
antibody for cancer and it made DRL the first company anywhere in the world to produce a 
biosimilar referencing Roche's originator $6 billion cancer drug MabThera (fig 3). 
 
Gradually, DRL increased R&D investments for its biological division and by 2014, it reached 
35% of total R&D expenses. By 2010, DRL was operating with three biological dedicated 
manufacturing facilities and a team of more than 300 scientists and engineers. At this stage, 
DRL adopted a strategy of commercialising its biosimilars in emerging markets as a step 
towards gaining approval in the US and Europe. This strategy allowed DRL two advantages. 
First, it helped the company to gather crucial real world experience and clinical data on the 
performance of its products and, second, it provided DRL an opportunity to generate revenue 
that could be utilised for developing drugs for advanced countries. Following on, in 2010, DRL 
began selling Rituximab in emerging markets at a 30-50% discount compared to the innovator 
brand.  
 
In 2012, DRL started planning to enter the highly regulated US and European markets. As part 
of that strategy, in June 2012, DRL formed an alliance with Merck Serono, a division of Merck 
KGaA, Germany, Merck KGaA is a global pharmaceutical company with proven expertise in 
developing, manufacturing, and commercialising biopharmaceuticals and chemical 
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compounds. The partnership aimed to co-develop and globally commercialise a portfolio of 
biosimilar compounds in oncology, primarily focused on monoclonal antibodies (mAbs). The 
alliance allowed DRL to mitigate the risks involved in developing a biosimilar (a cost estimated 
at $100-200 million). By 2013 DRL started applying for FDA and EMA approval. In 2013, the 
company filed a US investigational new drug (IND) application for its Rituximab biosimilar 
and peg-filgrastim and received permission to proceed with the Phase-I trials in 2014. At 
present, DRL is involved in planning, designing and executing clinical studies under these 
INDs. 
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Fig 3 Dr Reddys Laboratories Ltd  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sets up biotech as separate business division and starts working on building biotech R&D in Hyderabad  
 
1999 
2001 
2004 
2007 
2009 
2010 
2011 
2013 
Develops company’s first biosimilar filgrastim, used in treatment of cancer, and launches in the Indian 
domestic market   
Hires Dr. Cartikeya Reddy from Genentech to lead biotech division, it gives boost to biotech R&D activities 
 
Becomes the first company anywhere in the world to launch Rituximab, a biosimilar of Roche 6 billion drug       
 
Sets up three biological dedicated manufacturing facilities and enters emerging country markets  
 
Launches derbepotein alpha in India, at the time of launch became only company to sell this drug in India, 
Forms a partnership with Merck Serono to co-develop and market oncology products in overseas markets  
Launches pegfilgrastim, a drug used in cancer treatment in India and other emerging countries  
 
Initiates phase I clinical trials in USA for Rituximab and Peg Filgrastin in partnership with Merck   
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6.0 Analysis and discussion  
The firms in this study show the employment of different strategies that integrate, build and 
reconfigure internal and external competencies to address the changing environment. In other 
words, the development of dynamic capabilities.   
 
6.1 Strategies that develop technological capabilities  
The case study evidence summarised in Table 2, lists the main activities that we have linked to 
increasing capabilities in biosimilars and the strategies employed to gain these. Analysis of 
Indian firms biosimilar product portfolios reveals that manufacturing capabilities and not the 
therapeutic class, form the basis of specialisation, cost and knowledge advantage. These firms 
are balancing risk in biosimilar production and marketing by building a very wide biosimilar 
portfolio covering several therapeutic areas and promising candidates. Regulatory handling 
capabilities are concerned with preparation of safety, quality and efficacy data, in a format 
required by regulatory authorities.  
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Table 2 Technological Capabilities for biosimilar development (Annual Reports, 2013; 
Analysts presentation, company reports) 
 
 
Table 2 shows that all firms have invested in the development of biosimilar capabilities by 
setting up dedicated biosimilar R&D and manufacturing facilities. This has created a basic 
knowledge base for identifying and acquiring knowledge from external sources.  
 
Firms in our study lack certain R&D resources in-house to carry out activities such as 
bioprocess development and cell-line development. These firms have adopted a combination of 
 Biocon Cipla DRL 
Biotechnology 
R&D 
1999 2010 1999 
Dedicated 
Biological 
R&D  
Bangalore, India Goa, India Hyderabad, India  
Biosimilar 
manufacturin
g capabilities 
Integrated facilities in 
India and Malaysia  
 Integrated facility 
in India  
Key R&D 
acquisitions  
Acquisition of Cuban 
company CIMAB’s 
49% stake in their 
joint venture, Biocon 
Biopharmaceuticals 
Pvt Ltd (BBPL) in 
2010 
Acquisition of 
Mabpharm, an Indian 
biotech company, 
Acquisition of 25% 
stake in BioMab, a 
Shanghai based 
biotech company. 
 
In-licensing of 
biosimilars  
 2    
Clinical trials/ 
Clinical 
Research 
organisation 
 
Clinigene, in-house 
CRO established in 
2000.  
 Partnership with 
CRO Argenta (UK) 
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three strategies to fill these gaps: i) increasing R&D investments and setting up in-house clinical 
research organisations (CRO), ii) establishing collaborations with overseas firms and research 
institutes and iii) hiring scientists with extensive experience of biotech R&D.  
 
Increasing R&D investments and setting up in-house clinical research organisations was 
notably accomplished by DRL which established biotech as a separate business division and 
invested in building separate R&D facilities. One senior R&D manager at DRL commented: 
“When we started we knew this represented totally a new capability, only few 
companies have done it and only few companies knew how to do it. So I think we 
pursued it with that understanding and therefore acted on it like we want to build a new 
set up from scratch. And to me that’s really what served us well. We didn’t think of it 
as a business plan, we didn’t think of it as a product, even while we obviously had 
business plan that drove the investment. The end game was not about when I get revenue 
out of the next molecule because if you look at it that way then there is no reason to 
invest in this. The only way this entire investment makes sense is to understand that it 
represents a huge proportion of pharma pipeline and you are running it as a right to 
participate in the new segment of the industry.” (Interview/2014) 
 
Biocon also set up an in-house CRO to develop absorptive capacity in biosimilar 
commercialisation. DRL on the other hand has preferred to out license biosimilar clinical trials 
rather than investing in in-house building of these complimentary capabilities.   
 
Strategies which involve establishing collaborations with overseas firms and research institutes, 
particularly in advanced countries allow firms to tap into external knowledge sources, fill 
knowledge gaps and reduce development costs. This is exemplified by the early starters DRL 
and Biocon, which developed collaborations to develop basic capabilities in biological R&D.  
(Table 3).   
 
Table 3 Key R&D collaborations (Annual reports, company website) 
Year Indian 
firm 
MNC Nature of alliance 
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A typical strategy involves Indian firms handling early product development and early stage 
clinical trials, while overseas firms produce the compound and handle late-stage clinical trials. 
An R&D head at a leading firm commented,  
“Most companies might say that they are collaborating because it’s expensive but truth 
is that they are collaborating because it’s difficult. All the capabilities needed are 
practically like a full-fledged pharma company but what you are doing is biosimilar. 
And that’s the dilemma. From Pfizer to virtual biotech company based in San Francisco 
have something to offer. Now we are focusing on more global development efforts so 
we are investing in technologies, investing in partnerships that can give us some late 
stage capabilities and that can help us access markets like the US and Europe.”  
This finding suggests that firm level dynamic capability development cannot happen in 
isolation and external linkages with other firms formed a key part of Indian firms’ dynamic 
capability development strategies, even though the nature and motive of their relationships 
differs in each firm.  
 
2004 Biocon Vaccinex (USA) Co-develop at least four therapeutic 
antibody products 
2006 Biocon Cuban Institute of Molecular 
Immunology (CUBA) 
Development of antibody for treating cancer  
2007 Biocon Abraxis (USA) Filgrastim GCSF (product development and 
marketing) 
2009 Biocon Amylin Co-development of novel peptide hybride 
for treatment of diabetes.  
2009 Biocon Mylan (USA) Co-development of five MAbs 
2010 Biocon Pfizer (USA) Insulin and analogues (Pfizer: marketing 
and sales)  
2012 DRL Merck Serono 
(Switzerland)  
MAbs (joint development) 
2014 Biocon Advaxis Inc (USA)  Co-development of its lead drug candidate 
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The strategic hiring of scientists as demonstrated by all case studies, allows firms to acquire 
specific knowledge in biosimilar production, development and regulation. Analysis suggests 
clear differences however, in Cipla’s motives for hiring compared to other case study firms. 
Cipla’s hiring is focused on filling top management positions in marketing, regional markets 
and strategy while hiring in other firms is targeted towards improving biotechnology R&D 
knowledge. This corresponds to Cipla’s strategy of building a biosimilar business model around 
strengths in marketing and distribution capabilities.  
 
6.2 Strategies that develop market capabilities  
This section considers the capabilities required in the downstream post market phase. In 
assessing market capabilities, factors include; the global diversity of a company’s markets, 
management of the product portfolio in each therapeutic segment, presence of distribution and 
sales network infrastructure and the ability to create local partnerships to facilitate market entry. 
Table 4, lists the factors present in the data, that indicate market capability in biosimilars and 
the strategies employed to gain these capabilities. 
    
Table 4 Market capabilities: Entry into international markets and partnerships (Annual 
Reports, 2013) 
 Biocon  Cipla DRL  
Biosimilars marketed 
in India   
7  1  4  
Biosimilars sold in 
emerging country 
markets 
Insulin in 40 
countries and 
Glaringe insulin in 5 
countries  
 Presence in small 13 
emerging markets with local 
partners  
Biosimilars marketed 
in advanced 
countries  
Completed Phase III 
trials in EU for 
Glaringe insulin 
 
 
 Phase I clinical trials in USA 
for Rituximab and Peg 
Filgrastin in partnership with 
Merck   
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Indian firms have extensive presence in advanced country markets whether measured through 
their exporting or foreign investment activities (Table 4). The marketing capabilities and 
strategies used for entering international small molecule generics market have provided these 
Indian firms a vital springboard to enter international biosimilar markets.  Cipla, and DRL for 
example have long established marketing and distribution networks. This has created 
significant complimentary capabilities (Teece, 1986) and in-depth understanding of the 
overseas market which facilitates entry of Indian firms into international biosimilar markets.  
Evidence points to Indian firms reverting to strategies prevalent amongst pharma firms in the 
pre -1990 era; targeting the rest of the world (excluding advanced country markets) and 
domestic markets for growth. The Head of Strategy of a leading Indian firm points out, 
 
“Taking the emerging country market route helps us do two things: one, stay close to 
our purpose of accelerating access to affordable biosimilars in emerging countries and 
second, to access short term revenue that de-risks our business journey and makes 
business more sustainable.” (Interview/2014) 
 
Couched in a more socially conscious rhetoric there is a simple strategy of entering the market 
and reducing the rent of a monopoly supplier when patent protection has been removed. The 
more compelling question is why emerging country markets are initially targeted when 
reimbursement structures and higher prices in advanced country markets offer higher returns. 
The evolving nature of regulatory systems in advanced country markets and demands for 
extensive data creates a higher level of risk and investment for Indian firms. A regulatory head 
comments, 
Market sharing 
agreements with 
overseas firms  
 
Partnership with 
Pfizer (2009-2012) 
Partnership with 
Mylan (2010) 
Partnership with 
CCM pharma to enter 
Malaysian and Brunei 
markets (2013) 
 Collaboration with Merck 
Serono to enter Europe 
market by 2017 
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“It’s really accumulating that evidence that costs money. To compete in the US and 
Europe you need that money and it is highly unlikely that an Indian firm can do that 
across multiple products as it will break the R&D budget of any Indian firm.” 
(Interview, 2014) 
 
The strategy of targeting emerging markets additionally offers Indian firms opportunities to 
collect necessary clinical data on safety, which may aid the application to regulatory authorities 
in the West.  
 
Table 4 reveals some key subtle differences in terms of modes of entry used by each firm to 
internationalise their biosimilar business. It suggests that Indian firms used three different 
routes for setting up of manufacturing facilities in overseas countries: greenfield investments, 
acquisitions and joint ventures. Biocon is using green field investment and the partnership route 
while Cipla is adopting the acquisition route to expand in overseas markets. Biocon has set up 
a manufacturing plant in Malaysia and established a partnership with Mylan and other firms to 
serve advanced country and other emerging country markets. In contrast Cipla is acquiring a 
stake in other biotech firms and converting many of its existing overseas partnerships in 
manufacturing, sales and distribution into its own subsidiaries through equity deals and joint 
ventures.  
   
6.3 Heterogeneity in business models; path dependence versus managerial vision 
Finally, case study analysis shows evidence of a relationship between managerial vision and 
heterogeneity observed in firms. Trajectories of the firms are partly shaped by path 
dependencies, but also by the disruptive forces created by new managerial strategies and the 
expansion of firms into the biosimilar area. 
 
In transitioning to biosimilars, the firms chose different paths – Biocon and DRL are adopting 
an organic route of investing in R&D, collaborating with overseas firms and building strong 
human resources, and Cipla through an in-licensing, acquisition and joint venture route.  Biocon 
and DRL adopted an organic growth model based on building strong upstream drug 
development capabilities.  Biocon was a biotechnology company from the beginning and set up 
a clinical research organisation, which created path dependency and complementary 
competencies. Similarly, DRL has shown strong technological capabilities in biotechnology 
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R&D evidenced by its product portfolio. In contrast, Cipla focused on an acquisition model 
with pre-existing capabilities in marketing and distribution. Cipla lacked experience of reverse 
engineering large and complex molecules but was driven by strong cash flow, ambitious 
leadership and well-established marketing networks in advanced countries. Cipla is 
compensating for a lack of R&D capabilities by in-licencing technology and products from 
overseas firms and using existing distribution and marketing capabilities to build their 
biosimilar business.  
 
These differences in strategy both give rise to, and result from, capabilities acquired through 
different means. Evidence highlights significance of complimentary capabilities but also 
reveals that some pre-existing capabilities learned through experience with small molecule 
generics markets constrained development of biosimilar R&D and regulatory capabilities. All 
firms under study invested in setting up new R&D infrastructure, organisational practices and 
regulatory capabilities as existing infrastructure and practices became secondary, though not 
completely obsolete in the new environment. Studies of other industries suggest that some 
resources, processes and capabilities that served firms well in the past become obsolete where 
there is a new technology and discarding these activities forms important aspect of adding new 
knowledge (Leonard-Barton, 1992). With biosimilars, a significant degree of risk is evident in 
the projected future growth of the market, the evolving regulation and the position of emerging 
country suppliers. Biosimilar capabilities are therefore being developed in parallel with small 
molecule generics. This means that biosimilars will likely be developed by large firms which 
have sufficient resources and capabilities to employ either the organic or acquisition strategies 
that we identify.  
 
While existing technological competence played an important role as did the firms’ historical 
trajectories, two other factors also have important roles to play in defining the strategy mixes 
adopted by Indian biosimilar producers: primarily ‘firm specific managerial dynamic 
capabilities’, and also ‘inter-organisational learning’ through the observation of compatriot 
leader firms. Firm specific dynamic managerial capabilities are thus driving reconfiguration 
strategies and shaping firm level technological learning in Indian firms. The vision of Dr Yosuf 
Hamied that Cipla could be a significant global player in biosimilars led to change in the 
management team and drove the company’s ambitious acquisition strategy. Further Dr 
Hamied’s focus on cheap drugs and disbelief in strong patent laws lies at the heart of acquisition 
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focused strategy adopted by Cipla. In contrast, Biocon and DRL are guided by R&D focused 
visions of Kiran Muzumdar Shaw and Dr Anji Reddy respectively.  Biocons direction was 
guided by the ambition of Kiran Muzumdar Shaw to draw global recognition for Indian firms 
in the biotechnology sector. Anji Reddy’s aim was to take DRL into the top ten of global 
pharmaceutical companies and he believed that this could be done through innovative R&D. 
These leaders have knowledge and expertise to sense opportunities and reconfigure 
organisational resources, competencies and structures, reinforcing significance of dynamic 
managerial capabilities in influencing strategic change (Helfat and Martin, 2015).  
 
Firms chose different paths and business models to create a market- technological capabilities 
mix, however, the strategies firms have used to achieve these transitions have also been 
borrowed from each other. Late entrant Cipla is following early entrant Biocon’s example and 
has invested in the development of complimentary capabilities by setting up clinical research 
organisations (CRO’s). De-risking biosimilar investment through targeting emerging country 
markets was initiated by Biocon but is now followed by other Indian firms. It suggests that 
inter-organisational learning through observation of other firms’ successful strategies, has 
significantly influenced the strategies pursued by firms and may be as important as own firm 
learning. In this sense the heterogeneity in business models and inter-organisational learning 
initiated by firms constitute a search and experiment exercise for the whole industry. 
 
7.0 Conclusion  
Analysis of heterogenity in strategies to exploit biosimilar opportunities points towards an 
evolution of Indian firms’ capabilities throughout the production process, starting from 
upstream expansion of the knowledge base and re-orientation of R&D to downstream 
enhancement of partnership and marketing capabilities in emerging markets.  It is evident that 
Indian firms are reconfiguring existing strategies by targetting emerging country markets to de-
risk their investments and entering into collaborations and partnerships with overseas firms and 
research institutes to augment their own capabilities.  
 
We have attempted to draw a distinction and show how managerial vision contributes to the 
development of other capabilities in the firm. The influential role played by firm specific 
dynamic managerial capabilities in shaping firm strategies highlights and reinforces the link 
between heterogeneity and managerial capabilities (Helfat and Martin, 2015).  The link is a 
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complex interrelationship with one set of capabilities influencing another. Evidence suggests 
that learning processes and business models in case study firms are clearly shaped by owners 
with strong vision and beliefs. For example, DRL and Biocon models reflect R&D focused 
vision of Dr Reddy and Kiran Muzumdar Shaw while Cipla is following Dr Hamied's vision of 
aggressive entry into emerging country markets.  This reinforces Helfat and Martin’s (2015) 
argument that the dynamic managerial capabilities concept provides a broad lens for 
understanding managerial impact on strategic change across a wide range of settings.  
 
Most probably the winning combination will include certain elements of the different models 
and will prove to be a robust way in which to overcome the key challenges of talent 
unavailability and resource constraints. However evidence from this research does point 
towards the emergence of the organic growth model as the dominant and long term growth 
model for Indian and other emerging country firms. These insights have strategic implications 
for generic pharmaceutical firms operating in other advanced and emerging countries.  
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